Trial Profile

Weekly Paclitaxel-Carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negative (ER-[Estrogen Receptor], PR-[progesterone receptor], HER2-[human epidermal growth factor receptor 2]) Metastatic Breast Cancer. A Multicenter Phase I-II Study.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Sep 2016 Biomarkers information updated
30 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
06 Feb 2013 Planned end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com